Cargando…

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential

Idelalisib is a first-in-class, oral, selective phosphatidylinositol 3-kinase δ inhibitor that offers a chemotherapy-free option for patients with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Clinical trials in iNHL have evaluated idelalisib as monotherapy and as combination th...

Descripción completa

Detalles Bibliográficos
Autor principal: Barrientos, Jacqueline C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876096/
https://www.ncbi.nlm.nih.gov/pubmed/27274288
http://dx.doi.org/10.2147/OTT.S102573